Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study.
Crohn’s disease
anti-TNF failure
treatment failure
treatment response
ustekinumab
vedolizumab
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
29 Jun 2021
29 Jun 2021
Historique:
received:
27
05
2021
revised:
22
06
2021
accepted:
23
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Multiple studies have described the effectiveness of ustekinumab (UST) and vedolizumab (VDZ) in patients with Crohn's disease (CD) failing anti- Tumor necrosis factors (TNFs); however, the effectiveness of VDZ or UST as a third-class biologic has not yet been described. In this retrospective multicenter cohort study, we aimed to investigate the effectiveness of VDZ and UST as a third-class biologic in patients with CD. Two-hundred and four patients were included; 156/204 (76%) patients received VDZ as a second- and UST as a third-class therapy (group A); the remaining 48/204 (24%) patients received UST as a second- and VDZ as a third-class therapy (group B). At week 16-22, 87/156 (55.5%) patients and 27/48 (56.2%) in groups A and B, respectively, responded to treatment ( Third-class biological therapy was effective in more than half of the patients with CD. No differences in effectiveness were detected between the use of VDZ and UST as a third-class agent.
Sections du résumé
BACKGROUND
BACKGROUND
Multiple studies have described the effectiveness of ustekinumab (UST) and vedolizumab (VDZ) in patients with Crohn's disease (CD) failing anti- Tumor necrosis factors (TNFs); however, the effectiveness of VDZ or UST as a third-class biologic has not yet been described.
AIMS AND METHODS
OBJECTIVE
In this retrospective multicenter cohort study, we aimed to investigate the effectiveness of VDZ and UST as a third-class biologic in patients with CD.
RESULTS
RESULTS
Two-hundred and four patients were included; 156/204 (76%) patients received VDZ as a second- and UST as a third-class therapy (group A); the remaining 48/204 (24%) patients received UST as a second- and VDZ as a third-class therapy (group B). At week 16-22, 87/156 (55.5%) patients and 27/48 (56.2%) in groups A and B, respectively, responded to treatment (
CONCLUSION
CONCLUSIONS
Third-class biological therapy was effective in more than half of the patients with CD. No differences in effectiveness were detected between the use of VDZ and UST as a third-class agent.
Identifiants
pubmed: 34209880
pii: jcm10132914
doi: 10.3390/jcm10132914
pmc: PMC8268494
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Am J Gastroenterol. 2016 Aug;111(8):1147-55
pubmed: 27296941
Therap Adv Gastroenterol. 2020 Jul 9;13:1756284820936536
pubmed: 32695231
J Gastroenterol. 2018 Sep;53(9):1048-1064
pubmed: 29869016
Inflamm Bowel Dis. 2017 Aug;23(8):1394-1402
pubmed: 28671873
J Crohns Colitis. 2019 Jul 25;13(7):864-872
pubmed: 30715258
Clin Gastroenterol Hepatol. 2017 Sep;15(9):1427-1434.e2
pubmed: 28365485
J Dig Dis. 2018 Aug;19(8):468-474
pubmed: 30039533
J Crohns Colitis. 2018 Jan 24;12(2):245-257
pubmed: 29077833
Dig Liver Dis. 2020 Oct;52(10):1148-1155
pubmed: 32828693
Aliment Pharmacol Ther. 2012 Sep;36(5):459-66
pubmed: 22784296
Aliment Pharmacol Ther. 2020 Jul;52(1):123-134
pubmed: 32441396
Aliment Pharmacol Ther. 2018 Apr;47(7):896-905
pubmed: 29430672
Clin Gastroenterol Hepatol. 2019 Jan;17(1):130-138.e7
pubmed: 29857145
Aliment Pharmacol Ther. 2020 May;51(10):948-957
pubmed: 32249966
Clin Gastroenterol Hepatol. 2021 Apr;19(4):668-679.e8
pubmed: 32629124
J Crohns Colitis. 2014 Nov;8(11):1516-22
pubmed: 24996483
Ther Adv Chronic Dis. 2016 Jul;7(4):208-14
pubmed: 27433311
Aliment Pharmacol Ther. 2020 Aug;52(3):563-564
pubmed: 32656831
J Gastroenterol. 2017 Jul;52(7):788-799
pubmed: 27722996
Aliment Pharmacol Ther. 2020 Jun;51(11):1039-1046
pubmed: 32291786
Autoimmun Rev. 2014 Jan;13(1):24-30
pubmed: 23792214
Therap Adv Gastroenterol. 2016 Jul;9(4):513-26
pubmed: 27366220
Dig Dis Sci. 2017 Jun;62(6):1590-1596
pubmed: 28357697
Inflamm Bowel Dis. 2018 Mar 19;24(4):849-860
pubmed: 29562271
Aliment Pharmacol Ther. 2018 Feb;47(3):346-355
pubmed: 29226370
United European Gastroenterol J. 2018 Apr;6(3):439-445
pubmed: 29774158
Aliment Pharmacol Ther. 2020 Aug;52(4):669-681
pubmed: 32656800
Aliment Pharmacol Ther. 2020 Jul;52(1):135-142
pubmed: 32412134
Scand J Gastroenterol. 2015 Apr;50(4):379-86
pubmed: 25636030
Inflamm Bowel Dis. 2017 Jan;23(1):97-106
pubmed: 27930408
United European Gastroenterol J. 2020 Nov;8(9):1076-1085
pubmed: 32807038
Inflamm Bowel Dis. 2017 Mar;23(3):404-408
pubmed: 28178003
Gut. 2020 Jul;69(7):1206-1212
pubmed: 31980448
J Crohns Colitis. 2019 Oct 28;13(11):1401-1409
pubmed: 30989232
Inflamm Bowel Dis. 2018 Aug 16;24(9):1876-1882
pubmed: 29668916
Clin Gastroenterol Hepatol. 2021 Jan;19(1):104-110
pubmed: 32109634
Aliment Pharmacol Ther. 2016 May;43(10):1090-102
pubmed: 27038247
Inflamm Bowel Dis. 2016 Jul;22(7):1662-9
pubmed: 27306072
United European Gastroenterol J. 2021 Jun;9(5):581-589
pubmed: 34077627
Aliment Pharmacol Ther. 2018 Mar;47(5):588-595
pubmed: 29315694
Inflamm Bowel Dis. 2018 Oct 12;24(11):2442-2451
pubmed: 29788318
Aliment Pharmacol Ther. 2016 Dec;44(11-12):1199-1212
pubmed: 27714831
Aliment Pharmacol Ther. 2017 May;45(9):1232-1243
pubmed: 28252210
J Crohns Colitis. 2020 Oct 5;14(10):1488-1493
pubmed: 32318735
Dig Liver Dis. 2019 Sep;51(9):1232-1240
pubmed: 31202609
Nat Rev Gastroenterol Hepatol. 2014 Apr;11(4):243-55
pubmed: 24393836
Aliment Pharmacol Ther. 2020 Sep;52(6):1017-1030
pubmed: 32770851
Clin Gastroenterol Hepatol. 2021 Jul;19(7):1366-1376.e2
pubmed: 32668338
J Crohns Colitis. 2020 Mar 13;14(3):332-341
pubmed: 31504343